Three separate experiments were performed to evaluate the reproducibility of detecting the six spiked analytes, in addition to three putative ovarian cancer biomarkers, IL-8, EGFR, and osteopontin, alongside the FDA-approved marker CA-125. This evidence concerns the gene SPP1 and ovarian cancer.